SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cadila Healthcare gains on the buzz of its plans of launching molecule for diabetes dyslipidemia

19 Mar 2013 Evaluate

Cadila Healthcare is currently trading at Rs 740.00, up by 1.10 points or 0.15% from its previous closing of Rs 738.90 on the BSE.

The scrip opened at Rs 744.75 and has touched a high and low of Rs 746.10 and Rs 733.00 respectively. So far 3260 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 5 has touched a 52 week high of Rs 964.00 on 12-Sep-2012 and a 52 week low of Rs 695.00 on 16-Apr-2012.

Last one week high and low of the scrip stood at Rs 767.00 and Rs 735.30 respectively. The current market cap of the company is Rs 15087.92 crore.

The promoters holding in the company stood at 74.79% while Institutions and Non-Institutions held 16.32% and 8.89% respectively.

Cadila Healthcare, part of the ZydusCadila group, is reportedly planning to launch an indigenously developed molecule for diabetes dyslipidemia, which is expected to be called Saroglitizar. The company has been working on a new molecule since 2004. At present, the company has several molecules under its research pipeline which it hopes to bring to the market.

Recently, Zydus Cadila received tentative approval from USFDA for Doxepin Hcl tablets in the strengths of 3 mg and 6 mg. The estimated sale in 2012 as per IMS for Doxepin Hcl, which falls in the neuropsychiatry segment, was $15.5 million.

Zydus Lifesciences Share Price

939.20 3.20 (0.34%)
16-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1693.15
Dr. Reddys Lab 1221.25
Cipla 1230.75
Zydus Lifesciences 939.20
Lupin 2326.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×